Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance shows increased R&D expenses and a net loss, but cash reserves are sufficient until late 2026. Product development is progressing, with Phase II trials on track and partnerships supporting expansion. However, the reliance on soquelitinib and competitive pressures pose risks. The Q&A highlights strategic focus but lacks clarity on some future plans. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement in either direction.
Key Financial Performance
Research and Development Expenses $7.9 million in Q2 2025 compared to $4.1 million in Q2 2024, a $3.8 million increase primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel-related costs.
Net Loss $8 million in Q2 2025 compared to $4.3 million in Q2 2024. The increase includes a $400,000 noncash loss related to Angel Pharmaceuticals and a $2 million noncash gain from the change in fair value of Corvus' warrant liability in Q2 2025, compared to a $1.8 million noncash gain and $600,000 noncash loss in Q2 2024.
Stock Compensation Expense $1.3 million in Q2 2025 compared to $800,000 in Q2 2024, reflecting an increase in stock-based compensation.
Cash, Cash Equivalents, and Marketable Securities $74.4 million as of June 30, 2025, compared to $52 million as of December 31, 2024. The increase was driven by $35.7 million in cash proceeds from the exercise of common stock warrants, including $2 million from warrants exercised by the CEO.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Soquelitinib development for atopic dermatitis: Significant progress with Phase I trial data showing favorable safety and efficacy. Cohort 3 demonstrated a mean percent reduction of EASI score of 64.8% at 4 weeks, with 50% achieving EASI-75. Plans for Phase II trial with 200 patients globally.
Soquelitinib for T-cell lymphoma: Phase III trial ongoing with interim data expected in late 2026. Phase I trial results to be presented at the American Society of Hematology meeting in December.
Ciforadenant in renal cell cancer: Phase II trial completed, with data to be presented at the ESMO meeting in October.
Market expansion in China: Angel Pharmaceuticals, partner in China, plans Phase Ib/II trial of soquelitinib for atopic dermatitis with 48 patients, aligning with global Phase II trial direction.
Financial position: Cash, cash equivalents, and marketable securities totaled $74.4 million as of June 30, 2025, up from $52 million at the end of 2024. Current cash expected to fund operations into Q4 2026.
Stock compensation expense: Increased to $1.3 million in Q2 2025 from $800,000 in Q2 2024.
Focus on ITK inhibitors: Advancing soquelitinib development and exploring next-generation ITK inhibitors for broader applications in dermatology, oncology, and autoimmune diseases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Increased R&D Expenses: Research and development expenses rose significantly from $4.1 million in Q2 2024 to $7.9 million in Q2 2025, driven by higher clinical trial and manufacturing costs for soquelitinib and increased personnel-related costs. This could strain financial resources and impact profitability.
Net Loss Increase: The net loss for Q2 2025 was $8 million, nearly double the $4.3 million loss in Q2 2024. This reflects higher operational costs and could challenge the company's financial sustainability.
Reliance on Cash Reserves: The company expects its current cash reserves to fund operations only until Q4 2026, indicating a potential need for additional funding or revenue generation to sustain operations beyond this period.
Regulatory and Clinical Risks: The success of soquelitinib and other drugs is contingent on regulatory approvals and successful clinical trials. Any delays or failures in these areas could significantly impact the company's strategic objectives.
Market Competition: The company faces competitive pressures in the pharmaceutical industry, particularly in the fields of dermatology and oncology, which could affect market share and revenue potential.
Dependence on Partnerships: The company relies on partnerships, such as with Angel Pharmaceuticals in China, for clinical trials and market expansion. Any issues in these partnerships could disrupt operations and strategic plans.
Pipeline Diversification Risks: The company's heavy focus on soquelitinib and ITK inhibitors may pose a risk if these programs fail to deliver expected results, as there appears to be limited diversification in the pipeline.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cash Runway: Based on current plans, the company expects its current cash to fund operations into the fourth quarter of 2026.
Phase I Trial Extension Cohort 4: The company has amended the Phase I trial protocol to include an extension Cohort 4, evaluating 24 patients at the Cohort 3 dose of 200 milligrams twice per day for 8 weeks, with data anticipated in the fourth quarter of 2025.
Phase II Trial for Atopic Dermatitis: The company plans to initiate an international, randomized, placebo-controlled, double-blinded Phase II trial for soquelitinib in atopic dermatitis by the end of 2025. The trial will enroll approximately 200 patients and will evaluate different dosing regimens over a 12-week treatment period.
Angel Pharmaceuticals Collaboration: Angel Pharmaceuticals plans to initiate a Phase Ib/II trial of soquelitinib for atopic dermatitis in China, enrolling 48 patients and studying a 12-week treatment period with an additional dosing option of 400 milligrams once daily.
Phase III Trial for Relapsed PTCL: The company continues to enroll patients in its registrational Phase III trial of soquelitinib in relapsed PTCL, with interim data expected in late 2026.
Phase II Trial for ALPS: Patient enrollment is ongoing in the Phase II trial of soquelitinib for ALPS, with potential initial data in late 2025 or early 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company thinking about next indications and financially supporting opportunities for Cifo in autoimmune disease?
A:The company is considering follow-up indications for soquelitinib, focusing on maintaining a presence in dermatology with hidradenitis suppurativa and exploring pulmonary diseases like asthma. They believe their drug's mechanism of action could provide a novel approach to asthma. However, they acknowledge the difficulty in pursuing all indications but emphasize their efficiency in maximizing product value.
Q:What are the next steps for the Cifo program after the renal update at ESMO?
A:The company will evaluate the data presented at ESMO, focusing on response rates, durability of responses, and progression-free survival (PFS). Based on the results, they will decide on the next steps for the program. The study was conducted by the Kidney Cancer Consortium with the company providing the drug and financial support.
Q:How is enrollment progressing for soquelitinib in PTCL, and is the guidance for data in late 2026 still intact?
A:Enrollment is progressing according to plan with about 20 centers open in the U.S. and Canada. The guidance for data in late 2026 remains intact.
Q:What was the decision process for the Phase II trial design for atopic dermatitis?
A:The Phase II trial design includes 200 patients divided into four cohorts (200 Q.D., 200 B.I.D., 400 Q.D., and placebo). The design follows FDA guidance to study different doses to determine the lowest effective dose and higher doses' efficacy. The trial is placebo-controlled, blinded, and uses standard endpoints like mean percent change in EASI, EASI-75s, and IGA-0 and 1s. Enrollment is expected to take 12-15 months, with results in 18 months.
Q:When can results for the Phase II trial for atopic dermatitis be expected?
A:Enrollment is expected to take 12-15 months, with results anticipated in 18 months. The trial will start in December, and factors like oral administration, novel mechanism of action, and allowing patients who failed systemic therapies are expected to facilitate enrollment.
Q:What are the plans for the next-generation ITK inhibitor?
A:The company did not provide specific details due to intellectual property reasons but mentioned that ITK plays roles in T cell receptor signaling, Th2 cytokine production, and apoptosis. They believe their compounds might work better for some indications or mechanisms than others.
Q:Review of Unclear Management Responses
A:The company avoided providing specific details about the next-generation ITK inhibitor due to intellectual property reasons, leaving the response vague and lacking clarity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Angel Pharmaceuticals
Aydin Huseynov
CEO Chairman
CEO Dr
Chairman Aydin
Chemistry Inc
Co Founder
Co Inc
Conference result
Corvus Pharmaceuticals
Corvus warrant
Financial Results
II trial
Inc Research
Kubow Real
Lea Chief
Pharmaceuticals Update
Phase II
Real Chemistry
Research Division
Results Conference
Update Financial
afternoon Corvus
area
cancer
enrollment Phase
gain change
loss Angel
medicine
noncash gain
noncash loss
soquelitinib
value Corvus
warrant liability
CRVS Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call summary presents a mixed picture. Basic financial performance shows increased net loss and stock compensation, but cash reserves have grown. Product development updates are promising, with multiple trials underway. Market strategy lacks clarity due to abstract rejection and unclear trial plans. Financial health is stable, with increased cash reserves. Shareholder return plans are not mentioned. Q&A reveals potential trial delays and management's lack of clarity on certain issues, balancing positive trial progress. Overall, the sentiment is neutral due to balanced positives and negatives, and the lack of market cap information limits the prediction's precision.
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed outlook. The company's financial performance and product development show promise with ongoing trials and potential applications in multiple indications. However, there are uncertainties regarding trial outcomes and management's reluctance to provide clear guidance on certain metrics. The Q&A section reveals some positive analyst sentiment but also highlights risks and unclear management responses. The lack of guidance and need for additional funding are concerns. Overall, the stock price reaction is expected to be neutral in the short term, as the positive aspects are balanced by uncertainties and financial challenges.
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed outlook. Financial performance shows increased R&D expenses and a net loss, but cash reserves are sufficient until late 2026. Product development is progressing, with Phase II trials on track and partnerships supporting expansion. However, the reliance on soquelitinib and competitive pressures pose risks. The Q&A highlights strategic focus but lacks clarity on some future plans. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement in either direction.
CRVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
